Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NOS2 | P35228 | 5/20 | 0.58 |
| ▸ | NOS1 | P29475 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026402 | 0.92 | MAPT (0.67) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL18546942 | 0.90 | MAPT (0.54) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL18547352 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL4637044 | 0.89 | MAPT (0.61) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL18546959 | 0.89 | ALDH1A1 (0.53) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL4636292 | 0.87 | MAPT (0.62) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL4635816 | 0.86 | NOS2 (0.59) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL4635973 | 0.86 | ALDH1A1 (0.52) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL18547377 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTALDH1A1LMNAPOLB | |
| SCHEMBL18546967 | 0.85 | MAPT (0.49) | SMN1; SMN2MAPTALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-6583155-B2 | Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1315490-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309593-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030078419-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-4470989-A | Neuroleptic n-oxacyclyl-alkylpiperidine derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-09-11 | — | — | US | disclosed |
| EP-0068261-A1 | N-oxacyclyl-alkylpiperidine derivatives, their preparation, pharmaceutical preparations containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078419-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | SMN1; SMN2 3550/4885MAPT 3187/4885ALDH1A1 2313/4885 |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | SMN1; SMN2 1950/4885MAPT 4473/4885ALDH1A1 528/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | SMN1; SMN2 2009/4885MAPT 4471/4885ALDH1A1 517/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | SMN1; SMN2 2009/4885MAPT 4471/4885ALDH1A1 517/4885 |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | SMN1; SMN2 4614/4885MAPT 2904/4885ALDH1A1 1241/4885 |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | SMN1; SMN2 3320/4885MAPT 2221/4885ALDH1A1 839/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | SMN1; SMN2 4614/4885MAPT 2904/4885ALDH1A1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.